. 2021 Oct 25;12:664533. doi: 10.3389/fendo.2021.664533

Table 2.

Study characteristics of the subgroup analyses/main study comparing SGLT-2 inhibitors VS placebo in patients with T2DM and HF.

Study	Intervention	Sample size, n	Age, years#	Female sex, %	Type of HF included	HF status
CANVAS	Canagliflozin	803	64.1 ± 8.3	43.1	Both preserved and reduced	With history of HF, but not known if had existing HF.
	Placebo	658	63.4 ± 8.3	45.9	Both preserved and reduced	With history of HF, but not known if had existing HF.
DAPA-HF	Dapagliflozin	1075	66.3 ± 9.9	22.3	Reduced only	Existing HF
	Placebo	1064	66.7 ± 9.8	22.3	Reduced only	Existing HF
DECLARE–TIMI 58	Dapagliflozin	318/908*	NR	NR	Reduced only	Including existing HF, with history of HF but without existing reduced EF
	Placebo	353/1007	NR	NR	Reduced only
EMPEROR-Reduced	Empagliflozin	927	66.8 ± 10.0	22.7	Reduced only	Existing HF
	Placebo	929	66.6 ± 10.3	23.5	Reduced only	Existing HF
SOLOIST-WHF	Sotagliflozin	608	69 (63-76)	32.6	Both preserved and reduced	Diagnosis with HF ≥3 months prior to Screening, and with history of hospitalization for HF
	Placebo	614	70 (64-76)	34.9	Both preserved and reduced

T2DM, type 2 diabetes mellitus; HF, heart failure; NR, not reported; EF, ejection fraction.

*Existing HF only/Combined existing HF and with history of HF.

^#Age was presented as mean ± SD or median (interquartile range).